[Efficacy of setegis administration after transvesical adenomectomy].

We studied efficacy ofsetegis in different doses for therapy of lower urinary tract symptoms in patients after transvesical adenomectomy (TVAE). The analysis of case histories of 41 patients after open TVPE for prostatic adenoma has shown that setegis (terazosin) is effective in therapy of urinary bladder overactivity which is present in the majority of patients after TVAE. Compared to the controls, terazosin-treated patients improved urination more noticeably. Thus, alpha-adrenoblocker segetis is effective and safe in therapy of imperative voiding disorders with symptoms of urgent incontinence in patients after TVAE. Use of this drug can significantly contribute to successful postoperative rehabilitation of postadenomectomy patients. Setegis can be recommended for wide clinical practice.

[The results of long-term permixon treatment in patients with symptoms of lower urinary tracts dysfunction due to benign prostatic hyperplasia]. / Rezul'taty dolgosrochnogo primeneniia permiksona u bol'nykh s simptomami narusheniia funktsii nizhnikh mochevykh putei, obuslovlennymi dobrokachestvennoi giperplaziei predstatel'noi zhelezy.

The trial enrolled 155 patients (mean age 65 years) with documented benign prostatic hyperplasia and lower urinary tracts symptoms (LUTS) (IPSS > 6). All the patients received permixon in a dose 160 mg twice a day for 2 years. The data on 130 patients eligible for assessment were processed statistically by dynamics of IPSS, quality of life (QOL), index of sexual function (MSF-4), size of the prostate, urodynamic and biological parameters which were estimated in 6 (V6), 12 (V12), 18 (V18) and 24 months (V24). Clinical examination with registration of all side effects was made each 3 months. Permixon was found to noticeably reduce IPSS and QOL and increase maximal urine flow speed. The size of the prostate diminished insignificantly. Sexual function remained unchanged for 1 year and improved markedly within the second year (p = 0.001). Permixon had no effect on the level of prostate-specific antigen. Plasma hormones (testosterone, DHT, estradiol, LH, androstendion) did not change. Nine patients developed 10 side effects but they were unrelated to the treatment.

[The current approach to assessing the degree of risk in performing urological operations]. / Sovremennyi podkhod k otsenke stepeni riska vypolneniia urologicheskikh operatsii.

Upon analysis of all the available classification of urological operative risk the authors conclude that classification proposed by the Moscow Anesthesiology Scientific Society meets current requirements as it allows for the opinion of the surgeon, anesthesiologist and functional diagnosis specialist.

[The intracavernous injection of Edex (prostaglandin E1) in the treatment of erectile impotence in persons in older age groups]. / Vnutrakavernoznoe vvedenie "Edeksa" (prostaglandina E1) v lechenii érektil'noi impotentsii u lits starshikh vozrastnykh grupp.

Erectile impotence may be of neuropathic, vascular, psychogenic and hormonal origin or may be caused by their combination. This impotence occurs in up to 10% of sexually active men. The injection of prostaglandin E1 (PGE1) into the penile cavernous bodies results in venous occlusion warranting maximal erection. Edex (PGE1) was given to 23 patients aged 43-68 years (mean age 58.9 years) suffering from impotence as a result of prostatic cancer (5 cases), postprostatic adenomectomy condition (8 cases), chronic prostatitis (4 cases), diabetes mellitus (4 cases), chronic alcoholism (1 case), spinal trauma (1 patient). The dose (from 5 to 20 micrograms) was adjusted individually. Good, satisfactory and poor effects were achieved in 86.2, 13.0 and 4.3% of the patients, respectively. In prostatic cancer males on hormone therapy and after adenomectomy the effect was obtained in 76.9% (in 10 of 13 males). An old age is not a contraindication for intracavernous injections of Edex.

[The prognostic significance of determining androgen receptors in prostatic cancer]. / Prognosticheskoe znachenie opredeleniia retseptorov androgenov pri rake predstatel'noi zhelezy.

The role of androgen receptors (ARs) registration in cytosol tumor fraction has been investigated in 86 new cases of prostatic cancer. The frequency of occurrence and mean ARs levels in the tumor were found dependent on the disease stage and tumor differentiation. Well-differentiated against moderately and poorly differentiated prostatic cancers contain ARs in 73% and 39% of cases, respectively, in concentrations 10-100 fmol/mg protein and 100 fmol/mg protein, respectively. Patients with well-differentiated prostatic cancer at stage T1-4N0M0 and 10-100 fmol/mg protein ARs in the tumor tend to achieve longer remissions compared to patients with ARs-free tumors or tumor comprising ARs in concentrations surpassing 100 fmol/mg protein. No significant correlation exists between remission duration in patients on radiation treatment combined with estrogen therapy and the presence, levels of ARs in the tumor.

[The cardiovascular and thromboembolic complications of intravital estrogen therapy in middle-aged and elderly patients with prostatic cancer]. / Serdechno-sosudistye i tromboémbolicheskie oslozhneniia pozhiznennoi éstrogenoterapii bol'nykh rakom predstatel'noi zhelezy v pozhilom i starcheskom vozraste.

Cardiovascular and thromboembolic complications arising as a result of 1-16-year estrogen therapy were evaluated in 105 prostatic cancer patients. The incidence of the complications was higher in those who had pretreatment cardiological or vascular load. The latter caused death in half of the patients. Preventive and therapeutic measures to control the complications, prognosis signs are indicated.

[Incidence and nature of metastases of prostatic cancer based on autopsy data]. / Chastota i kharakter metastazirovaniia raka predstatel'noi zhelezy po dannym autopsii.

Pathways of lymphatic and hematogenic spread for prostatic cancer were studied versus tumor stage and patients' age. Metastases into regional lymph nodes were the most frequent, while bony and visceral metastases ranked second and third, respectively. Age-related peculiarities of dissemination were identified. The data obtained do not support the traditional standpoint that bones are the most frequent sites of prostatic cancer dissemination.